Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Axe Cap view

CYTK’s Aficamten: A New Player in HCM with Growth Potential

Cytokinetics' aficamten shows promising trial results that could reshape hypertrophic cardiomyopathy treatment markets.

South African investors tend to overlook biotech firms like Cytokinetics, but its recent clinical results warrant attention. Aficamten, targeting hypertrophic cardiomyopathy (HCM), demonstrated improved cardiac function, outperforming key competitors in both obstructive and non-obstructive forms. While FDA approval for Myqorzo, a direct competitor, came in late 2025, Cytokinetics plans to seek regulatory approval for a broader HCM label by 2026, potentially tapping into a larger patient base. Although none of these firms trade on the JSE, the USD/ZAR provides a useful lens: a stronger rand could enhance local appetite for offshore biotech exposures in dollar terms, but rand weakness may suppress that demand. Investors looking for indirect exposure might consider global funds with biotech holdings or the currency angle. Risks include regulatory setbacks or market acceptance challenges, which could delay commercial rollout. For now, watch USD/ZAR trends alongside clinical milestones;. this is just our opinion and not financial advice